U.S. Markets closed

Amid Bristol-Starboard Duel Over Celgene, Here's What's Really Key

ALLISON GATLIN
Amid Bristol-Starboard Duel Over Celgene, Here's What's Really Key

Bristol-Myers Squibb and activist shareholder Starboard Value are still tussling over the looming $74 billion Celgene acquisition, but analysts are looking ahead to a key proxy vote.